메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Waters and BD's Biosciences & Diagnostic Solutions Busine…

Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growth Creates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Increases annual recurring revenue to over 70% with over 80% of revenue coming from iconic market-leading brands Anticipate approximately $345 million in annualized EBITDA synergies by 2
- 김갑성 기자
- 2025-07-14 19:00
Zepp Health Corporation to Report Second Quarter 2025 Finan…

Earnings Call Scheduled for 9:30 p.m. ET on August 3, 2025 MILPITAS, Calif., July 14, 2025 -- Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it will report its second quarter 2025 unaudited financial results on Sunday, August 3, 2025. Management will hold a conference call at 9:30 p.m. Eastern Time on Sunday, August 3, 2025. Listeners may access the call by dialing: US (Toll Free): +1-888-346-8982
- 김갑성 기자
- 2025-07-14 19:00
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B…

Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D Funds to accelerate Alzheimer's and immune disease drug development, expanding GAIA-based pipeline SEOUL, South Korea, July 14, 2025 -- The Series B round saw strong participation from both existing and new investors, demonstrating high industry confidence in Illimis Therapeutics' vision and technology. Eight existing investors, including DSC Investment, Woori Venture Partners, Korea Development Bank, Aju IB
- 김갑성 기자
- 2025-07-14 15:38
Bridge Capture™ enables sensitive, scalable liquid biopsy…

Clinical study in Scientific Reports shows Bridge Capture™ detects key mutations from blood samples in metastatic colorectal cancer patients TURKU, Finland, July 14, 2025 -- Genomill Health, a biotechnology company pioneering simplified targeted library preparation for next-generation sequencing announces the results of a clinical pilot study published in Scientific Reports, demonstrating the high sensitivity of its Bridge Capture™ technology for mutation profiling in cell free DNA of metastatic colorectal cancer patients. Study shows that Bridge Capture™ matches the sensitivi
- 김갑성 기자
- 2025-07-14 15:00
Bridge Capture™, 대장암 액체 생검 파일럿 연구에서 확장 가능한 고감도 분석 기술…

사이언티픽 리포트 (Scientific Reports)에 게재된 임상 연구, Bridge Capture™로 전이성 대장암 환자의 혈액 샘플에서 주요 돌연변이 검출 투르쿠, 핀란드, 2025년 7월 14일 -- 차세대 염기서열분석을 위한 간소화된 표적 라이브러리 전처리 기술을 선도하는 생명공학 기업 지노밀 헬스(Genomill Health)가 Bridge Capture™ 기술의 높은 민감도를 입증한 임상 파일럿 연구 결과를 과학 저널 '사이언티픽 리포트(Scientific Reports)'에 발표했다. 이번 연구는 전이성 대장암 환자의 세포 유리 DNA(cell-free DNA)를 분석하여, Bridge Capture™가 미세방울 디지털 PCR(ddPCR)과 동등한 민감도로 돌연변이를 검출할 수 있음을 보여줬다. ddPCR은 해당 분야의 '골드 스탠더드'로 평가받는 기술이다. Bridge Capture™는 무제한 확장 가능한 유전자 패널, 간단하고 비용 효율적인 워크플로를 통해 분산형 NGS 검사를 가능하게 한다는 점에서 큰 주목을 받고 있다. 이 연구는 아리 리스티매키(Ari Ristimäki) 교수 그룹
- 김갑성 기자
- 2025-07-14 15:00
MGI Tech Won Green World Award for Sustainable Contribution…

AUCKERLAND, New Zealand, July 14, 2025 -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, is proud to announce that it has been awarded the Green World Champion in the Environmental Improvement: Conservation & Wildlife Projects sector of Green World Award 2025. This award recognizes MGI's groundbreaking efforts in utilizing genomics technology to support the conservation of Thai mangrove species. MGI's collaboration with the Thai National Omics Center aims to introduce genetic diversity in
- 김갑성 기자
- 2025-07-14 14:11
Imugene Announces Outstanding Response Rates from th…

[ 메디채널 김갑성 기자 ] Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall Response rate (ORR): 6 total CR and 3 PR in Phase 1b trial of azer-cel, an allogeneic off-the-shelf CD19 CAR T therapy in relapsed diffuse large B-cell lymphoma (DLBCL), an aggressive type of blood cancer First patient remains cancer free at 15 months and ongoing with additional patients having durable responses at 2, 5, and 11 months+ and durability data continuing to mature Patients in the trial have previously failed at
- 김갑성 기자
- 2025-07-14 12:43
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EP…

SHANGHAI, July 14, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP3445407, which covers its GPC3-targeted CAR-T cell therapy. On July 3, 2025, a U.S.-based biotechnology — the sole appellant among the original two opponents — formally withdrew its appeal against the EPO Opposition Division's earlier decision to maintain the patent. This withdrawal rend
- 김갑성 기자
- 2025-07-14 08:00
호주 치과의사들, 쿤밍 글로벌 심포지엄에서 스마티의 하악 재배치 장치 기술에 찬사

[ 메디채널 김갑성 기자 ] 임상 전문가들, S8-SGTB 장치가 치료 결과를 가속하고, 환자 만족도를 높이며, 제2급 부정교합에 대한 비침습적 해결책을 제공한다고 호평 쿤밍, 중국 2025년 7월 12일 -- 스마티 덴티-테크놀로지(Smartee Denti-Technology)가 최근 중국 쿤밍에서 열린 글로벌 심포지엄(Global Symposium)에서 호주의 치과 전문가와 파트너를 초청해 하악 재배치 기술과 그 임상 적용 사례를 집중적으로 조명했다. 특히 제2급 골격성 부정교합을 위한 혁신적인 S8-SGTB 장치가 주목을 받았다. 호주 임상의들은 이 장치가 정형적(orthopedic) 및 치아 교정적(orthodontic) 효과를 제공하는 동시에, 치료 기간이 짧고 환자 친화적 디자인이라며 찬사를 보냈다. 시드니 월드타워 치과(Dental Clinic @ World Tower Sydney)의 노크스 킴(Dr. Knox Kim) 원장은 다음과 같이 말했다. "과거에는 성장기 환자의 제2급 부정교합을 치료하기 위해 투명 교정 시작 전 트윈블록 장치를 사용해야 했다. 개선을 확인하는 데 최소
- 김갑성 기자
- 2025-07-12 15:39
Bio Investments Group (BIG) and International Vaccine Institu…

ZUG, Switzerland and SEOUL, July 11, 2025 -- The Bio Investments Group AG (BIG), a leading global healthcare-technology transfer platform, and the International Vaccine Institute (IVI), an international organization dedicated to advancing vaccine discovery, development, and delivery, today announced the signing of a Memorandum of Understanding (MoU) to establish a strategic collaboration aimed at accelerating local vaccine manufacturing, clinical evidence generation, and capacity building across Africa and the Middle East. This partnership underscores a shared vision to enhanc
- 김갑성 기자
- 2025-07-11 23:08

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-08-21_THU

2025-08-20_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 21일 10시 40분